Atea Pharmaceuticals
AVIRAtea Pharmaceuticals is a Boston-based, publicly traded biotech (Nasdaq: AVIR) focused on transforming the treatment of severe RNA viral infections with oral antivirals. The company's core strategy is built on its expertise in nucleos(t)ide chemistry and virology, targeting the viral RNA polymerase with a high barrier to resistance. Its most advanced asset is a pan-genotypic HCV regimen in Phase 3, with topline data expected in 2026, and it is expanding its pipeline to include other RNA viruses like hepatitis E. Atea's partnership with Roche for its COVID-19 candidate, AT-527, provides validation and potential commercial reach.
AVIR · Stock Price
Historical price data
AI Company Overview
Atea Pharmaceuticals is a Boston-based, publicly traded biotech (Nasdaq: AVIR) focused on transforming the treatment of severe RNA viral infections with oral antivirals. The company's core strategy is built on its expertise in nucleos(t)ide chemistry and virology, targeting the viral RNA polymerase with a high barrier to resistance. Its most advanced asset is a pan-genotypic HCV regimen in Phase 3, with topline data expected in 2026, and it is expanding its pipeline to include other RNA viruses like hepatitis E. Atea's partnership with Roche for its COVID-19 candidate, AT-527, provides validation and potential commercial reach.
Technology Platform
A proprietary platform of oral purine nucleos(t)ide prodrugs designed to inhibit the highly conserved viral RNA-dependent RNA polymerase (RdRp), offering a high barrier to resistance and potential for pan-genotypic activity across multiple RNA viruses.
Pipeline
24| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Bemnifosbuvir (BEM) + Placebo | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | Phase 3 | |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (S... | HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | |
| Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir | HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | |
| Bemnifosbuvir + Ruzasvir | Chronic Hepatitis C Virus | Phase 2 | |
| AT-752 + Placebo | Dengue Fever | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
In HCV, Atea faces established giants Gilead and AbbVie, differentiating with a protease inhibitor-free, pan-genotypic oral regimen. In COVID-19, it competes with Pfizer's Paxlovid and Merck's Lagevrio, leveraging its nucleotide analog mechanism and Roche partnership. For hepatitis E, AT-587 targets an untreated market with no direct competitors, offering a pioneering opportunity.